- Home
- GHRS vs NRIX Comparison
GHRS vs NRIX Comparison
Compare GHRS & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GHRS
- NRIX
- Stock Information
- Founded
- GHRS 2018
- NRIX 2009
- Country
- GHRS Ireland
- NRIX United States
- Employees
- GHRS N/A
- NRIX N/A
- Industry
- GHRS Biotechnology: Pharmaceutical Preparations
- NRIX Biotechnology: Pharmaceutical Preparations
- Sector
- GHRS Health Care
- NRIX Health Care
- Exchange
- GHRS Nasdaq
- NRIX Nasdaq
- Market Cap
- GHRS 774.1M
- NRIX 728.6M
- IPO Year
- GHRS 2021
- NRIX 2020
- Fundamental
- Price
- GHRS $13.10
- NRIX $9.38
- Analyst Decision
- GHRS Strong Buy
- NRIX Strong Buy
- Analyst Count
- GHRS 8
- NRIX 14
- Target Price
- GHRS $30.63
- NRIX $29.07
- AVG Volume (30 Days)
- GHRS 307.7K
- NRIX 1.2M
- Earning Date
- GHRS 11-13-2025
- NRIX 10-09-2025
- Dividend Yield
- GHRS N/A
- NRIX N/A
- EPS Growth
- GHRS N/A
- NRIX N/A
- EPS
- GHRS N/A
- NRIX N/A
- Revenue
- GHRS N/A
- NRIX $88,381,000.00
- Revenue This Year
- GHRS N/A
- NRIX $74.59
- Revenue Next Year
- GHRS N/A
- NRIX N/A
- P/E Ratio
- GHRS N/A
- NRIX N/A
- Revenue Growth
- GHRS N/A
- NRIX 41.86
- 52 Week Low
- GHRS $6.00
- NRIX $8.18
- 52 Week High
- GHRS $20.50
- NRIX $29.56
- Technical
- Relative Strength Index (RSI)
- GHRS 45.98
- NRIX 52.39
- Support Level
- GHRS $13.00
- NRIX $8.85
- Resistance Level
- GHRS $14.96
- NRIX $9.75
- Average True Range (ATR)
- GHRS 0.78
- NRIX 0.49
- MACD
- GHRS -0.00
- NRIX 0.15
- Stochastic Oscillator
- GHRS 28.46
- NRIX 76.21
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.